Brind.

Novartis, Takeda, and United Therapeutics signed data licensing deals with Tempus AI.

2 reports, 0 independent Updated Jul 2

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Novartis, Takeda, and United Therapeutics signed data licensing deals with Tempus AI.

Who's involved

What this event is mainly about

Tempus Novartis

Keep exploring

The entities involved

Tempus
biotechnology company based in Chicago, Illinois
- Tempus is scheduled to participate in a conference in New York City on September 4, 2025.Sun 01:41
- Tempus AI, led by Eric Lefkofsky, is acquiring Paige to enhance its digital pathology datasets.Sat 00:42
Novartis
Swiss-American multinational pharmaceutical corporation
- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
- GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Related events

Coverage

Newest first; wire copies grouped

Jul 2Unknown outlet
Jun 27Unknown outlet